<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 6:10<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If52a86616b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="I1c3ad730933c11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>6.</label.designator><headtext>Selection of a Transferee District</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f39c7de1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>6:10.</label.designator><headtext>Factors articulated by the Panel in selecting transferee district—Nature of pending actions</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>In addition to looking at the number of actions pending in various districts, the Panel will sometimes look at the nature of the actions. <eos/><bos/>One example of this exists in the case of multiple class actions. <eos/><bos/>This situation makes transfer likely.[<eos/><bos/><footnote.reference refid="If52aad706b3e11e99b03e53d6dd36aa2">1</footnote.reference>] Where the class actions are different in scope, the Panel may quite logically prefer transfer to the district where the broader action is pending.[<eos/><bos/><footnote.reference refid="If52aad726b3e11e99b03e53d6dd36aa2">2</footnote.reference>] The Panel has also transferred cases to a district where related MDL proceedings are pending.[<eos/><bos/><footnote.reference refid="If52aad736b3e11e99b03e53d6dd36aa2">3</footnote.reference>] The Panel may also look at the breadth of the claims asserted in several actions, and select as the transferee district the court having the most comprehensive case or cases.[<eos/><bos/><footnote.reference refid="If52ad4806b3e11e99b03e53d6dd36aa2">4</footnote.reference>]</paratext><eos/><eop/></para></section.body></section><author.footnotes><footnote ID="If52a86616b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If52aad706b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs5:24" w-pub-number="185218" ID="If52aad716b3e11e99b03e53d6dd36aa2">§ 5:24</cite.query>, above.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If52aad726b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914071" w-serial-number="2034977559" w-seq-number="00001" w-ref-type="RP" w-pub-number="0007903" ID="I67d5a5b16b3e11e99779f698461214a6">In re: Fluidmaster, Inc., 65 F. Supp. 3d 1397 (U.S.J.P.M.L. 2014)</cite.query> (broadest complaint in action pending in the chosen transferee district); <cite.query w-src-number="0304914071" w-serial-number="2026993395" w-seq-number="00002" w-ref-type="RP" w-pub-number="0004637" ID="I67d5a5b36b3e11e99779f698461214a6">In re Oreck Corporation Halo Vacuum Marketing and Sales Practices Litigation, 842 F. Supp. 2d 1380 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914071" w-serial-number="2010616942" w-seq-number="00003" w-ref-type="RP" w-pub-number="0004637" ID="I67d5a5b56b3e11e99779f698461214a6">In re Novartis Wage and Hour Litigation, 460 F. Supp. 2d 1382 (J.P.M.L. 2006)</cite.query> (action broader in scope pending in transferee district); <cite.query w-src-number="0304914071" w-serial-number="2005418869" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I67d5a5b76b3e11e99779f698461214a6">In re Pineapple Antitrust Litigation, 342 F. Supp. 2d 1348 (J.P.M.L. 2004)</cite.query> (action in transferee district includes both direct-and indirect-purchaser claims); <cite.query w-src-number="0304914071" w-serial-number="2003212305" w-seq-number="00005" w-ref-type="RP" w-pub-number="0004637" ID="I67d5a5b96b3e11e99779f698461214a6">In re Wireless Telephone Services Antitrust Litigation, 249 F. Supp. 2d 1379 (J.P.M.L. 2003)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If52aad736b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914071" w-serial-number="2004322194" w-seq-number="00006" w-ref-type="RP" w-pub-number="0004637" ID="I67d641f16b3e11e99779f698461214a6">In re Laughlin Products, Inc., Patent Litigation, 313 F. Supp. 2d 1380 (J.P.M.L. 2004)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If52ad4806b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914071" w-serial-number="2030714950" w-seq-number="00007" w-ref-type="RP" w-pub-number="0004637" ID="I67d6de316b3e11e99779f698461214a6">In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, 949 F. Supp. 2d 1365 (J.P.M.L. 2013)</cite.query> (transfer to district where both direct- and indirect-purchaser claims pending); <cite.query w-src-number="0304914071" w-serial-number="2031720220" w-seq-number="00008" w-ref-type="RP" w-pub-number="0000999" ID="I67d6de336b3e11e99779f698461214a6">In re Loestrin 24 Fe Antitrust Litigation, 2013 WL 5505369 (J.P.M.L. 2013)</cite.query> (same); <cite.query w-src-number="0304914071" w-serial-number="2030316402" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I67d6de356b3e11e99779f698461214a6">In re NeuroGrafix (&apos;360) Patent Litigation, 936 F. Supp. 2d 1376 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914071" w-serial-number="2029450545" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I67d6de376b3e11e99779f698461214a6">In re Frito-Lay North America, Inc. All Natural Litigation, 908 F. Supp. 2d 1379 (J.P.M.L. 2012)</cite.query> (action in transferee district encompasses all claims in litigation); <cite.query w-src-number="0304914071" w-serial-number="2006671811" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I67d6de396b3e11e99779f698461214a6">In re Federal Nat. Mortg. Ass&apos;n Securities Derivative &amp; “ERISA” Litigation, 370 F. Supp. 2d 1359 (J.P.M.L. 2005)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 6:10<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
